Index

a
abdominal compartment syndrome 112
abdominal tumors 94–95
ACE inhibitors 103–104, 110, 111–112
acepromazine 113, 138, 173, 242
acetaminophen (paracetamol) 166–167
acupressure 187
acupuncture 20, 138, 191–192
adaptation in animals 30
advance directives 207–208
adverse effects of treatment 201, 203–204
after-death care options 310–312
Agaricus Bio 98
airway collapse 115–117
description 115
emergency treatment 117
management 116–117
manifestations 115–116
trajectory/prognosis 115
airway inflammation 118–119
canine chronic bronchitis syndrome 119
description 118
feline chronic bronchitis 119
management 119
manifestations 118–119
trajectory/prognosis 118
airway parasites 118
albuterol 119, 176
allow natural death (AND) directive 208
alprazolam 171, 173
alternative medicine for cancer 98
aluminium hydroxide phosphate binder 106
Alzheimer disease in humans 137
amantadine 93, 169–170
American Animal Hospital Association (AAHA) 10, 79
American Association of Human–Animal Bond Veterinarians (AAH–ABV) 9
American Humane Association 253
American Veterinary Medical Association (AVMA) 8, 9, 211
euthanasia criteria 256
Guidelines for the Euthanasia of Animals 253
human–animal bond 1
veterinary ethics 64
aminophylline 116, 119
amitriptyline 169, 173
amlodipine 103, 111, 112
amyotrophic lateral sclerosis (ALS) in humans 141
AngioStop™ 97
angiotensin receptor blockers 103
animal charities, support for 309
animal cognition and emotion 1, 7–8
animal hospice, definition 6
animal hospice and human hospice compared 10–12
economic differences 11–12
ethical differences 10–11
euthanasia 10–11
legal differences 10–11
patient autonomy 10
right to die 10–11
animal hospice and palliative care (AHPC)
aims 5–6
care goals 200–201, 202–203
client information 65
definition 5
development of the field 2
developments in veterinary care 2
euthanasia, views on 10–11
funding of services 11–12
future developments 3
hospice options and accompanying rituals 307–309
animal hospice and palliative care (AHPC) (cont’d)
hospice philosophy 2–3
mission and vision 17–18
terminology and definitions 5, 6
animal hospice and palliative care (AHPC) team 6
loss-related issues 47–49
self-care 47–49
animal hospice models of care 73–79
animal hospice case managers 75
animal hospice sanctuaries/rescues 76
hospice in the veterinary clinic setting 73–74
hospice with specialized mobile veterinarians 74–75
animal palliative care, definition 6
animal welfare movement 7–8
anorectic ketosis 219
anorexia 177, 218–220
anthrozoology 1
antiangiogenesis therapy 97
antibiotic therapy 106, 116, 119, 120, 124, 127, 176
anticipatory grief 43–44, 309
anticonvulsants (antiepileptic drugs, AEDs) 169
anticruelty statutes 67
antiemetics 126
antioxidant therapy 127
anxiety
and stress 154
behavioral expressions 157
effect on pain perception 171
management 171–173
non-pharmacologic interventions 171
pharmacologic interventions 171, 173
anxiolytics, for dyspnea 174
aortic thromboembolism 113
appetite needs at the end of life 206–207
Argus Institute for Families and Veterinary Medicine 9
aromatherapy 242
aspiration pneumonitis/pneumonia 119–120, 223
Assisi International Animal Institute 9
Assisi Loop 188
assisted standing 183–184
assisted walking 184–186
asthma 118–119
atelectasis 223
azathioprine 124
azodyl 105
b Battista, Mary 8
Becker, Marty 62
behavioral needs of dogs and cats 155–156
benazepril 103, 111
benzodiazepines 138, 171, 173, 242
beta-blockers 111
betahanechol 140
bisphosphonates 92, 98
Bittel, Ella 9
body carriage, expression of fear 157
body mechanics, principles and techniques 302
bond-centered care 1, 41
bond-centered care in AHPC 41–54
AHPC team as source of support 49–50
AHPC team roles 49–51
caregiver grief 42–44
caregiver needs 41–44
educator role of the AHPC team 49
emotional SOAP 42, 44
extended services 51, 52
facilitator role of the AHPC team 50
referral guidance 50–53
resources related to pet loss and grief 50–54
self-care for the AHPC team 47–49
veterinary team non-medical roles and limitations 45–47
when the bond breaks 42–44
bone cancers 93–94
boredom in sick animals 160–161
brachycephalic airway obstruction syndrome 117–118
brain tumors 93
Brieger, Ludwig 238
bronchodilator therapy 116, 119, 174–176
Bronstein, Laura 22
Buddhism 63
budesonide 124
buprenorphine 104, 126, 127, 168, 178
burden of disease 81–82
burdens of care assessment of 205–206
hospice and palliative care goals 200–201, 202–203
practical considerations 206–208
quality of life issues 199–208
burn out
definition 300
in veterinary settings 287
ways to avoid 300–301
business management
controlled substances handling 77–79
ethical business practices 68–69
forms for caregivers 76–77, 78
information for caregivers 76–77, 78
informed consent 77, 78
paperwork 76–77, 78
tips on good management 76–79
Bustad, Leo 7
butorphanol 113, 116, 138, 168

C

cachexia 177, 218–220
cadaverine 238
calcitriol 8, 104
calcium channel blockers 111, 112
Campbell, Courtney 3
cancers in dogs and cats 89–99
abdominal tumors 94–95
alternative medicine 98
antiangiogenesis therapy 97
approach to end‐of‐life cancer patients 90
bone cancers 93–94
brain tumors 93
cancer vaccines 98
canine lymphosarcoma 91
chemoprevention 97–98
chemotherapy 90, 93, 94, 95, 97
chest cavity tumors 95, 96
comorbidities 96–97
gene therapy 98
head and neck cancer 92–93
hemangiosarcoma in dogs 94
immunonutrition 98
immunotherapy 91, 98
integrative medicine 98
metronomic chemotherapy 90, 93, 94, 95, 97
MOMP protocol 91
nasal passage cancer 92–93
neck tumors 92
options offered to the family 89–90
oropharyngeal tumors 92
palliative cancer medicine 95–98
paraneoplastic syndromes 89, 90
risk factors in dogs and cats 89
skin tumors 90–91
soft tissue tumors 90–91
targeted therapy 98
transitional cell carcinoma 94–95
tumors of the skin and soft tissues 90–91
canine chronic bronchitis syndrome 119
canine lymphosarcoma 91
cannabis 242
carboplatin 93
cardiorenal syndrome 112–113
caregiver placebo effect 157
caregiver self‐care 300–302
avoiding burnout 300–301
balancing responsibilities 301
exercise 300
lifting and handling techniques 301–302
managing time commitments of care 301
nutrition 300
physical labor of care 301–302
relaxation 300–301
time considerations of hospice care 301
utilizing proper body mechanics during care delivery 301–302
caregivers as members of the AHPC team 21
autonomy, sense of 267
awareness of signs of pain 226
caring for 299
control, sense of 267
coping strategies 299
death and dying, information on 227
decision making for the animal hospice patient 251–252, 263–266
definition 6
dignity issues 266
emotional distress 266
emotional needs 272–275, 276, 299
emotional needs related to the bond 41–44
emotional support for the journey 309–310
emotional wellbeing 206
forms for 76–77, 78
hygiene guidance 226–227
information for 76–77, 78
information from the veterinary nurse 225–227
information on death and dying 227
limitations of veterinary team support 45–47
needs of 5
non‐medical roles of the veterinary team 45–47
physical needs 299
psychologic reserve 267
psychological concern assessment 46–47
questions to address 299
resilience 267
safety guidance 226–227
self‐esteem issues 266
suicidal thoughts 47
support for their emotional needs 272–275, 276
support from the veterinary nurse 225–227
support role of the bond‐centered AHPC team 41–44
wellbeing 199
caring–killing paradox 261
carprofen 94, 97
Cassell, Eric 61
cats, causes of death 84
central alpha‐2 agonist 173
cervical spondylomyelopathy 143–144
Index
317

pleural effusion 112
positive inotrope 112
prerenal azotemia 112
pulmonary edema 110–112
respiratory distress 113
right-sided failure 109, 110
sodium-restricted
  diet 113–114
  vasodilator 112
constipation, pharmacology
  interventions 178
controlled substances, proper
  handling of 77–79
Cooney, Kathy 243
COPE problem-solving
  model 274
coping mechanisms in
  animals 30
corticosteroids 116, 124, 126
coughing
  in congestive heart
    failure 113
pharmacology interventions
  176
  suppressants 176
coxofemoral luxation 135
cremation 310
types of services 311–312
cruciate ligament rupture
  132–133
  cranial cruciate ligament
    rupture 132–133
cryotherapy 187
cultural values, influence on
  decision making 69
C. Guillermo 91
cyclophosphamide 97
cyclosporine 124
cyproheptadine 105, 106, 177
d
darbopoetin alfa (Aranesp)
  102–103
Dawson, Susan 64
death, causes of 81–85
  in cats 84
  in dogs 82–84
  in hospice private practice
    84–85
  neurologic organ system
    change 145
death and dying
  as a meaningful experience 2
  information for caregivers
    227
death rattle 238, 243
  in congestive heart failure 110
decision making for the animal
  hospice patient 251–252
  see also ethical
  decision making
decisional regret 64
decubital ulcers 224
degenerative
  myelopathy 140–141
dehydration
  assessment 215
  pharmacology interventions
    178
treating 220, 221
deracoxib 94
dexamethasone 91, 124, 138
dexethromorphan 116
diagnostic procedures,
  assessment of efficacy
  and adverse effects 205
diazepam 93, 107, 140, 173
digoxin 111
disease trajectories 85–87
disenfranchised grief 271
displacement behaviors 159–160
distress 153–162
  and quality of life 155–156
  and stress 153–154
  and suffering 155
  behavioral changes 159–160
  behavioral needs of dogs and
  cats 155–156
  defining 154–155
  human recognition in
    animals 156–162
  mental and emotional status
    assessment 216–217
  quality of life assessment 28–31
‘do not resuscitate’
  directives 207–208
documentation, importance in
  IDT care 21
dogs
  causes of death 82–84
  disease risk related to
    breeds 83–84, 94, 137,
    140–141, 142, 143, 144
Doka, Ken, Ph.D. 271
dolasetron 105, 176–177
donation banks 305
Downing, Robin 8
doxepin 138, 173
dry mouth (xerostomia) 179
dysphoria, pharmacology
  interventions 173–174
dyspnea
  pharmacology interventions
    174–176
  suffering caused by 120–121
e
ears, expression of fear 157
economics of human and animal
  hospice 11–12
Eddie’s Wheels 304
electroacupuncture 143
electrotherapy 144, 190–191
emotional SOAP 42, 44
emotional suffering in
  animals 29
emotional support, honoring the
  journey 309–310
emotional wellbeing, of patients
  and caregivers 206
enalapril 103, 111
end-of-life care for companion
  animals 2
  advance directives 207–208
  appetite needs 206–208
  clinical ethics 57–64
  goal of care 232
  hydration needs 206–207
  quality of life issues 31,
    199–200
  steroid treatment 207
End of Life Care Guidelines
(AAHA/IAAHPC) 10
enteral nutrition 219–220
ergonomics 301–302
erythrocyte-stimulating agents
(ESA) 102–103
Escherichia coli 106
esophagostomy tubes 219
essential oils 194–195
ethical business practices 68–69
ethical decision making in
AHPC 57–69
clinical ethics 57–64
contextual factors 59, 62–63
cultural values 69
decisional regret 64
financial considerations in
treatment
decisions 67–68
four-box approach 58–64
guiding client decision
making 65–66
guiding the euthanasia
decision 66–67
information provision 65
moral decision making
method 58–64
moral dimensions of clinical
considerations 58, 59, 60
pain consideration 59, 60–62
patient preferences 59, 63–64
professional ethics 64–69
proxy decision making 63–64
quality of life
consideration 59, 60–62
societal ethics 69
suffering consideration
59, 60–62
ethical responsibility 45
ethics 3
differences between animal and
human hospice 10–11
ethology 7
euthanasia
advance preparation and
education of caregivers
and family 253–255
advance preparation and
education of the
professional team
252–253
alternative to premature
euthanasia 5
and natural death, choice
between 231–32
and quality of life 31
and religious beliefs 63
and the right to die 10–11
caregiver advance preparation
and education 253–255
caring–killing paradox 261
decision making for the
animal hospice
patient 251–252
family advance preparation
and education 253–255
guiding the decision 66–67
hospice movement views
on 10–11
in the animal hospice 251–261
legal position 67
meanings of 3
of a healthy animal 66–67
premature 31
professional team advance
preparation and
education 252–253
refusal to carry out 66–67
role ambiguity for veterinary
professionals 68
euthanasia techniques 255–261
AVMA euthanasia criteria 256
choice of method 255–256
intracardiac injection
257–258
intrahepatic injection
259–260
intraperitoneal injection 259
intrarenal injection 260–261
intravenous injection 256–257
training in 252–253
extracorporeal shockwave
therapy 191
eyes, expression of fear 157
f
facial expressions, pain-related
157–158
family-centered care 2
family of the patient 21, 310
famotidine 91, 104, 176,
177, 178
fatigue, pharmacology
interventions 174
fear
and stress 154
behavioral expressions 157
vocalizations 157
Fear Free Veterinary Care 62
feeding tubes 219–220
feline chronic bronchitis 119
Feline Platinum
Performance® 98
fentanyl 121, 168
ferrets 82
FETCH (Functional Evaluation
of Cardiac Health) 34
fibrocartilagenous embolic
myelopathy 144
financial considerations of
hospice care
303–305
cost of diagnostics 304
cost of end-of-life care 304
cost of environmental
modifications 304
cost of medications 304
cost of other healthcare
providers 304
cost of the range of treatment
options 67–68
donation bank creation 305
equipment at reduced
cost 305
equipment recycling and
donations 305
equipment rental 305
help to defer costs 304–305
influence on treatment
decisions 67–68
memorial fund creation 305
pet health insurance 304
Index

First International Animal Hospice Symposium (2008) 9
fluid deficit calculation 220, 221
fluticasone 119
food preference tests 155
force feeding 105–106, 219
forms for caregivers 76–77, 78
Fosamax 92
four-box approach to ethical decision making 58–64
fractures of limbs 133–134
furosemide 110–111, 112, 121, 175–176

g
gabapentin 93, 149, 169, 173
gastrointestinal conditions 123–128
cholangitis/cholangiohepatitis syndrome 126–128
inflammatory bowel disease 123–125
pancreatitis 125–126
GAT protocol 93, 94
Gawande, Atul 96, 199
gene therapy 98
genetic diseases 141
glucocorticoids 119, 166
glycopyrrolate 243
Goldberg, M.E. 213, 214
green tea extracts 98
grief 7
and bereavement 267–272
caregiver emotional support 272–275, 276
complicated 5, 271–272
counseling 275, 276, 278–280
disenfranchised 271
in children 275–277
loss, understanding 267–268
models of the grieving process 269–272
normal grief 267–269
prolonged grief disorder 271–272
stage theory of 269
unresolved 5
when the bond breaks 42–44
guaifenesin 120
GUVQuest (Glasgow University Veterinary School) 33
h
haloperidol 242
hamsters 82
Hancock, Guy 8
handling and lifting techniques 301–302
Hankin, Susan 67
Harris, James 8
Hartmann and Kuffer’s Karnofsky’s Score Modified for Cats 34
healing touch 20
heartworm-associated respiratory complex 118
helping relationships, features of 48
hemp (Cannabis sativa) 242
herbal medicines and supplements 194
hip dislocation 135
hip dysplasia 135
Hippocrates 121
history of animal hospice early beginnings 8–9
organization and recognition 9–10
philosophical roots 7–8
publications 8–9
scientific roots 7–8
home hospice care assessment of the pet’s living space 302–303
environmental considerations 302–303
household and environmental modifications 303
hygiene 302
hospice, definition 5
hospice care see animal hospice and palliative care (AHPC) hospice philosophy 2–3
hospice-supported natural death 3, 6, 11
human–animal bond 1, 7, 211
human hospice movement 2, 7
human hospice services, costs and funding 11
human recognition of emotional states in animals 156–162
Humane Society of the United States 253
hydration needs at the end of life 206–207 see also dehydration
hydrocodone 113, 116, 168
hydromorphone 121, 167–168
hygiene and safety guidance for caregivers 226–227
hyperphosphatemia 106
hypokalemia 107, 112
i
iguanas, food preference tests 155
Illiopoulou QOL questionnaire 35
immunonutrition 98
immunotherapy 91, 98
inflammatory bowel disease 123–125
additional support therapy 124–125
clinical manifestations 123
description 123
disease trajectory 123
immunosuppressive therapy 124
medical support 124–125
nutritional support 125
palliative management 123–125
informed consent 77, 78
inositol hexaphosphate (IP6) 98
integrative and alternative medicine for cancer 98
integrative medicine in AHPC 193–196
interdisciplinary team (IDT) 5–6, 15–24
administrative support 24
benefits of the IDT approach 15–16
chaplain 291–294
collective ownership of goals 22
communication and collaboration 16, 21–24
differences in hospice and palliative care 16
documentation, importance of 21
enhanced case flow process 23
flexibility of members 22
in animal hospice and palliative care 16–17
in human hospice and palliative care 15–16
interdependence of members 22
operating a successful IDT 17–24
organizational characteristics, influence of 23
orientation of team members 18
personal characteristics, influence of 23
professional roles, influence of 22–23
reflection on the team’s functioning 22
roles and responsibilities 18–21
selection of team members 18
team meetings 21–22
training of team members 18, 23–24
International Association for Animal Hospice and Palliative Care (IAAHPC) 5, 9–10, 11, 65, 253
International Association of Animal Hospice 2
International Renal Interest Society (IRIS), staging system for CKD 101
intervertebral disc disease 141–143
description 141–142
diagnosis 142
electroacupuncture 143
Hansen type I 142
Hansen type II 142
management 143
manifestations 142–143
myelomalacia 142
sequela 142
surgery 143
trajectory/prognosis 142
Jonsen, Albert 58
Karnes, Barbara 233
keratoconjunctivitis sicca (KCS) 218
Kübler-Ross, Elizabeth 7, 269
lactulose 105, 178
laryngeal paralysis 137–138
laser therapy 188–190
Lavan’s CHQLS (canine health-related quality of life survey) 35
legal differences between animal and human hospice 10–11
Levinson, Boris 7
lidocaine 119
life-saving measures, and quality of life 199–200
lifting and handling techniques 301–302
linoleic acid 93
linolenic acid 93
lomustine 93, 97
loperamide 98
lorazepam 149, 171, 173
Lorenz, Konrad 7
luteolin 119
m
MacNair, Rachael 64
Mader, Bonnie 8
‘magic mouthwash’ 104, 178
magnesium sulfate (MgSO4) for nebulization 121, 174–176
maintenance fluids administration 220
Marocchino, Kathryn 9, 11
maropitant 104–105, 120, 126, 127, 176
masitinib 94, 95, 97, 98
massage 187
mast cell tumors (MCT) 90
McMillan, Frank 29, 32, 41, 216
McMillan’s Affect Balance Model 32–33
McMillan’s Quick Assessment QOL Questionnaire 33
medical manipulation 192–193
medication administration assessment 215
melatonin 149
meloxicam 92, 94, 97
melphalan 91
memorial funds 305, 309
mental health considerations 263–281
caregiving experience 263–266
caregiving impact 266–267
commemorating losses 277–278
counseling support 278–280
emotional support for caregivers 272–275, 276
grief and bereavement 267–272
grief counseling 275, 276
helping children cope with pet loss 275–277
mental health professionals contacting 278–280
role in the AHPC team 19–20, 46–47
when to contact 46–47
metformin 97
methadone 167, 170
methylprednisolone 124
metoclopramide 105, 126, 176, 177
metronidazole 124
metronomic chemotherapy 90, 93, 94, 95, 97
micturition disorders 139–140
bladder can be expressed with effort 140
bladder difficult or cannot be expressed 140
bladder easily expressed but has continuous leakage 140
description 139
management 139–140
manifestations 139
straining to urinate with spurts of urine produced 140
trajectory/prognosis 139
urine leakage when urine accumulates 140
Milani, Myrna 8
MiraLAX® 105, 178
mirtazapine 105, 106, 177
mitoxantrone 91, 94
mobility and activity assessment 215–216
mobility carts 223, 303, 304
mobility slings and harnesses 222–223
mobility support techniques 221–223
assisted standing aids 222–223
assisted standing exercises 222
mobility carts 223
position transition support 222
range of motion (ROM) exercises 222
standby assisted standing 222
weight shifting exercises 222
Modified Wisconsin Protocol 91
MOMP protocol (mechlorethamine, vincristine, melphalan, prednisone) 91
moral dimensions of clinical considerations 58, 59, 60
moral practice 3
morphine 167, 168
Morris, Patricia 243
mourning 267–268
mouth, expression of fear 157
mucolytics 176
muscle pain 134
musculoskeletal disorders 129–135
coxofemoral luxation 135
cruciate ligament rupture 132–133
fractures of limbs 133–134
muscle pain 134
osteoarthritis 129–132
National Hospice and Palliative Care Organization (NHPCO) 11
natural death 3
active death, types of 240–241
active dying, clinical signs management during 241–244
active dying changes 234–235
early stages 235–236, 239
late stages 236–238, 239
advance preparation and education of caregivers 232–234
advance preparation and education of hospice team 232–234
agitation management 242
agonal breathing 243
and euthanasia, choice between 231–232
anxiety management 242
cardiac dysfunction 243
caregiver advance preparation and education 232–234
conjunctival care 244
death rattle 243
death, signs of approach 236–238, 239
definition 6
environment of care 234
fatigue 242
fluids administration 244–245
food administration 244, 245–246
goals of end-of-life care 232
hospice team advance preparation and education 232–234
incontinence 244
medication administration 244, 246
mucosal care 244
pain management 241–242
prognostication 234–238
respiration 243
skin vitality, diminished 243–244
swallowing ability, loss of 242–243
time of death 238–241
views on 11
weakness 242
nausea and vomiting, pharmacology interventions 176–177
nebulization therapy 121, 174–176
nervous system disease 137–145
approach to 145
cause of death in dogs and cats 145
cervical spondylomyelopathy 143–144
degenerative myelopathy 140–141
fibrocartilagenous embolic myelopathy 144
nervous system disease (cont’d)
intervertebral disc disease 141–143
laryngeal paralysis 137–138
micturition disorders 139–140
vestibular disorders 144–145
neuromuscular electrical stimulation (NMES) 190, 191
Nightingale, Florence 211
Nikki Pet Hospice Foundation 9
NMDA receptor antagonists 169–170
non-maleficence principle 200
non-steroidal anti-inflammatory drugs (NSAIDs) 93, 94, 97, 166
adverse events 201
nursing care for seriously ill animals 211–228
activity assessment 215–216
advocacy for patient and caregiver 225
bedding 221
care delivery 217–225
care planning 212
comfort for the patient 217–218
dehydration assessment 215
discomfort other than pain, assessment for 213
education of caregivers 225–227
emotional status assessment 216–217
environment 221
hydration 220, 221
hygiene 220–221
intake 212
medication administration assessment 215
mental status assessment 216–217
mobility assessment 215–216
mobility support techniques 221–223
monitoring and assessments, ongoing 212–217
nurses’ medical roles 212–217
nutrition 218–220
ocular comfort 218
oral comfort 218
pain assessments 212–213, 214–215
pain management 217–218
recumbent patients 223–225
veterinary nurse role 211
nutrition of seriously ill animals 218–220

O
ocular comfort for the patient 218
odor of death 238
omega 3 polyunsaturated fatty acids (PUFA) 119
omeprazole 104, 120, 176, 177
OncoSupport 98
ondansetron 105, 120, 176
oral comfort for the patient 218
oral health, pharmacology interventions 178–179
oral ulcers, pharmacology interventions 178
osteoarthritis 129–132
causes 129
description 129
management 130–132
manifestations 130
trajectory/prognosis 129
other pets, effects on 21, 310
oxycodone 168
oxygen, for dyspnea 174, 175

P
pain
assessments by veterinary nurses 212–213, 214–215
awareness of signs of 226
behavioral changes 159–160
behavioral expressions 157–158
behavioral indicators of 165–166
clinical signs of 165
evaluation 31
hiding of pain by animals 158–159
human recognition in animals 156–162
pharmacologic protocols 170–171
pharmacologic treatment response assessment 171, 172
quality of life assessment 28–31
relief of all types of pain 2–3
species-specific signs of 214
pain management 204, 217–218
during active death 241–242
pharmacology for 166–170
pain scales 213, 215
palliative care 2, 5, 6
palliative sedation 6
palliative sedation to unconsciousness (PSU) 6
pancreatitis 125–126
paperwork 76
paracetamol (acetaminophen) 166–167
patient and caregivers, as members of the AHPC team 21
patient autonomy principle 10
patient-centered care, role of quality of life assessments 28
patient integrity 3
patient preferences 59, 63–64, 231–32
Pawspice concept 8, 9, 90
Pawspice Scale 34
pentamidine 98
pentobarbital 252–253
perpetration-induced traumatic stress 64
pet burial 310
pet cemeteries 310
pet health insurance 11–12, 304
Pet Hospice and Education Center 9
pet owner grief and bereavement 7
pet-sitters 20, 21
pharmaceuticals, proper handling of controlled substances 77–79
pharmacology interventions for symptom management 165–179
anorexia 177
anxiety 171–173
cachexia 177
constipation 178
cough 176
dehydration 178
dry mouth (xerostomia) 179
dysphoria 173–174
dyspnea 174–176
nausea 176–177
oral health 178–179
oral ulcers 178
pain 165–172
respiratory symptoms 174–176
weakness or fatigue 174
vomiting 176–177
phenobarbital 107
phenothiazine tranquilizers 173
phenoxybenzamine 140
phenylpropanolamine (PPA) 140
phenytoin sodium 253
pheromones 149, 242
physical medicine and rehabilitation 181–196
acupressure 187
acupuncture 191–192
assisted standing 183–184
assisted walking 184–186
balance techniques 186
benefits 181, 182
chiropractic care 192–193
definition 181
electrotherapy 190–191
extracorporeal shockwave therapy 191
guidelines for hospice and palliative care patients 181–182
laser therapy 188–190
medical manipulation 192–193
modalities delivered by caregivers and support staff 183–188
modalities that require professional application 188–193
neuromuscular electrical stimulation (NMES) 190, 191
propriocceptive techniques 186
pulsed signal therapy (PST) 190
range of motion (ROM) therapy 183
targeted pulsed electromagnetic field therapy (tPEMF) 188
therapeutic ultrasound 191
thermal modalities 187–188
traditional Chinese veterinary medicine 191–192
transcutaneous electrical nerve stimulation (TENS) 190–191
Tui-na manipulative therapy 187
physician-assisted suicide (PAS) 11
pimobendan 111, 112
piroxicam 94, 97
placebo effect 157
platelet-rich plasma (PRP) therapy 131–132, 133
Platinum Performance Plus® 98
pneumonia 119–120
aspiration pneumonitis/pneumonia 119–120
categories of 119–120
description 119–120
management 120
manifestations 120
trajectory/prognosis 120
polysulfated glycosaminoglycans (PSGAGs) 131
prazosin 140
prednisolone 119, 124, 127
prednisone 91, 116
preference tests 155
pregabalin 169
prevalence of diseases 81–85
PRICE acronym for fracture management 133–134
pro bono work 67
professional chaplains 288, 289–294
professional ethics 64–69
ethical business practices 68–69
financial considerations in treatment decisions 67–68
guiding client decision making 65–66
guiding the euthanasia decision 66–67
information provision 65
minimum levels of care 67
pro bono work 67
therapeutic triad 68
prolonged grief disorder 271–272
prolotherapy 133
proportionate palliative sedation (PPS) 6
propriocceptive and balance techniques 186
prosthetic devices 185–186
proxy decision making 63–64
psychiatrist, support from 46
psychological adaptation in animals 30
psychologist, support from 46
psyllium husk 178
pulsed signal therapy (PST) 190
putrescine 238
qualified mental health professionals see mental health professionals

quality of life (QOL)
AHPC patients 27–38
behavioral needs of dogs and cats 155–156
concept 27
end-of-life care issues 199–200
individual variation in impact of burdens of care 206
patient-centered care 28
treatment effects 199–208

quality of life (QOL) assessments 1–2
approaches to 31–35
development of 27–28
ideal QOL assessment tool 35–36
importance in end-of-life care 27–28
influence on end-of-life decision making 31
negative factors affecting QOL 31
pain evaluation 31
pain in animals 28–31
physical factors 32
positive factors affecting QOL 31
psychological adaptation in animals 30
psychological factors 32
reliability 32
social factors 32
specificity 32
steps in the process 36, 37
suffering in animals 28–31
tools 31–35
validity 32

rats, facial expressions of pain 158
recumbent patients
bladder palpation and assessment 223
decubital ulcers 224
defecation 223
mobilizing 224–225
nursing care 223–225
respiration assessment and support 223–224
skin care 224
urination 223
referral guidance 50–53
rehabilitation see physical medicine and rehabilitation
reiki 20
religious beliefs, and animal euthanasia 63 see also spiritual needs
renal disease, cardiorenal syndrome 112–113
resources, related to pet loss and client grief 50–54
respiratory distress 115–121
airway collapse 115–117
airway inflammation 118–119
brachycephalic airway obstruction syndrome 117–118
in congestive heart failure 113
pneumonia 119–120
suffering caused by dyspnea 120–121
respiratory symptoms, pharmacology interventions 174–176
respite care 20–21
responsibility grief 64
Revivin™ 97
right to die, and euthanasia 10–11
risedronate 92
rituals for the end-of-life and afterwards 307–309

Saunders, Dame Cicely 2, 11, 29
scopolamine 243
seizures, in chronic kidney disease 107
selegiline 149
self-administration of medication 155
serotonin antagonists 173
serotonin syndrome 149
Shanan, Amir 9, 11
Shearer, Tami 8, 9
Siegler, Mark 58
skin care for recumbent patients 224
social attachment in animals 1
social workers
role in the AHPC team 16, 19–20
support from 46
societal ethics, influence on decision making 69
Spirits in Transition 9
spiritual counseling 46–47
spiritual needs 285–294
caregivers 285–286
in hospice and palliative care 291
in veterinary practice 291
professional chaplains 288, 289–294
spiritual distress 286–287
spiritual history 287–289
when to call in the experts 289–291
spironolactone 111
stereotypies 30
steroids 176
adverse events 201
use in end-of-life care 207
Stowe, James D. 51
strains 134
stress and emotions 153–154
definitions 153
manifestations of 153–154
stress response 153–154
stressors 153
subcutaneous fluid therapy 178
sucralfate 104, 120, 178
suffering in animals
assessing quality of life 28–31
relief of 2–3
suicide prevention counselor 47
superoxide dismutase 1 (SOD1) gene mutation 141
supplements 150
surrogate decision making 287
symptom management
see pharmacology interventions for symptom management
t
T-Cyte 98
tail, expression of fear 157
targeted pulsed electromagnetic field therapy (tPEMF) 144, 188
targeted therapy for cancers 98
telomerase inhibition 97
tense ascites 112
terbutaline 116, 119
terminal sedation 6
terminology 3, 5, 6
theophylline 116, 119
therapeutic triad 68
therapeutic ultrasound 191
thermal modalities 187–188
thermotherapy 187–188
thiazide 111
Thick-It® 138
toceranib 94, 97, 98
torsemide 111
traditional Chinese veterinary medicine 131, 133, 138, 140, 150, 187, 191–192, 242
tramadol 93, 94, 149, 168–169
transcutaneous electrical nerve stimulation (TENS) 190–191
trazodone 94, 149, 173, 242
treatment adverse events 201, 203–204
burdens of care 205–206
efficacy assessment 204–205
quality of life effects 199–208
treatment-related consequences 201, 203–204
tricyclic antidepressants (TCAs) anxiety management 173
neuropathic pain management 169
trigger points 134
Tui-na manipulative therapy 20, 187
tylosin 124
tyrosine kinase inhibitors 97, 98
U
UK Farm Animal Welfare Council 8
unresolved grief 5
urinary tract infection 106
urination disorders 139–140
ursodiol 127
V
vestibular disorders 144–145
vestibular syndrome 144
veterinarian-assisted death 3
veterinarians, role and responsibilities 19
veterinary aid-in-dying (VAD) 3
veterinary nurses, role and responsibilities 19 see also nursing care of seriously ill animals
veterinary oath 5, 45, 68
veterinarians, role and responsibilities 19
VetMetrica tool 33–34
Villalobos, Alice 8, 9, 11, 34, 215
vitamin D 98
vocalizations, expression of fear 157
Voluntary Euthanasia Society 11
volunteers 20–21
W
weakness, pharmacology interventions 174
wheelchairs for pets 303, 304
Winslade, William 58
Wojciechowska QOL questionnaire 35
X
Xeloda® 94, 97
xerostomia (dry mouth) 179
Y
Yazbeck and Fantoni QOL tool 34
Yunnan Baiyao 92, 94, 95
Z
zoledronic acid 92